Interaction of Naloxone and Estrogen Receptor in Breast Cancer

Morphine and Metastasis

Volumn , Issue , 2013, Pages 15-29

  Johnson, Katherine N H ^a   Gupta, K ^a   Zaveri, Nurulain ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Astraea Therapeutics Inc   (Spain)

Author keywords

Angiogenesis; Breast cancer; EGF receptor; Estrogen receptor; G protein coupled receptors; Methylnaltrexone; Naloxone; Naltrexone; Opioid receptor; Therapy

Indexed keywords

EID: 84904734065     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-007-5678-6_2     Document Type: Chapter

References (61)

1. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM (2004) Her-2 amplification, her-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 10:5670-5676. doi:10.n58/1078-0432.CCR-04-011010/17/5670 [pii]
2. Aylsworth CF, Hodson CA, Meites J (1979) Opiate antagonists can inhibit mammary tumor growth in rats. Proc Soc Exp Biol Med 161:18-20
3. Belcheva MM, Szucs M, Wang D, Sadee W, Coscia CJ (2001) Mu-opioid receptor-mediated erk activation involves calmodulin-dependent epidermal growth factor receptor transactivation. J Biol Chem 276:33847-33853
4. Berkson BM, Rubin DM, Berkson AJ (2009) Revisiting the ala/n (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther 8:416-422. doi:8/4/416 [pii]10.1177/1534735409352082
5. Cadet P, Mantione K, Bilfinger TV, Stefano GB (2002) Morphine down regulates human vascular tissue estrogen receptor expression determined by real-time RT-PCR. Neuro Endocrinol Lett 23:95-100. doi:NEL230202A01 [pii]
6. Chen C, Farooqui M, Gupta K (2006) Morphine stimulates vascular endothelial growth factor-like signaling in mouse retinal endothelial cells. Curr Neurovasc Res 3:171-180
7. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H (2011) Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12:496-503. doi:S 1470-2045(11)70030-4 [pii] 10.1016/S1470-2045(11)70030-4
8. Donahue RN, McLaughlin PJ, Zagon IS (2009) Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am J Physiol Regul Integr Comp Physiol 296:R1716-R1725
9. Donahue RN, McLaughlin PJ, Zagon IS (2011a) Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood) 236:1036-1050. doi:ebm.2011.011121 [pii] 10.1258/ebm.2011.011121
10. Donahue RN, McLaughlin PJ, Zagon IS (2011b) The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol 122:382-388. doi:S0090-8258(11)00270-8 [pii]10.1016/j.ygyno.2011.04.009
11. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M (2000) Effect of single and compound knockouts of estrogen receptors alpha (eralpha) and beta (erbeta) on mouse reproductive phenotypes. Development 127:4277-4291
12. Emde A, Mahlknecht G, Maslak K, Ribba B, Sela M, Possinger K, Yarden Y (2011) Simultaneous inhibition of estrogen receptor and the HER2 pathway in breast cancer: effects of HER2 abundance. Transl Oncol 4:293-300
13. Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Yee D, Gupta K (2006) Naloxone acts as an antagonist of estrogen receptor activity in mcf-7 cells. Mol Cancer Ther 5:611-620. doi:5/3/611 [pii] 10.1158/1535-7163.MCT-05-0016
14. Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta K (2007) COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 97:1523-1531
15. Finley MJ, Happel CM, Kaminsky DE, Rogers TJ (2008) Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell Immunol 252:146-154
16. Fujioka N, Nguyen J, Chen C, Li Y, Pasrija T, Niehans G, Johnson KN, Gupta V, Kratzke RA, Gupta K (2011) Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg 113:1353-1364. doi:ANE.0b013e318232b35a [pii]10.1213/ANE.0b013 e318232b3 5 a
17. Gach K, Piestrzeniewicz M, Fichna J, Stefanska B, Szemraj J, Janecka A (2008) Opioid-induced regulation of mu-opioid receptor gene expression in the MCF-7 breast cancer cell line. Biochem Cell Biol 86:217-226
18. Gronemeyer H, Gustafsson JA, Laudet V (2004) Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3:950-964. doi:nrd1551 [pii]10.1038/nrd1551
19. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP (2002) Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 62:4491-4498
20. Gupta M, Yunfang L, Gupta K (2007) Opioids as promoters and regulators of angiogenesis. In: Maragoudakis ME, Papadimitriou E (eds) Angiogenesis: basic science and clinical applications. Transworld Research Network, Kerala, pp 303-317
21. Gururaj AE, Rayala SK, Vadlamudi RK, Kumar R (2006) Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res 12:1001s-1007s
22. Hall JM, Couse JF, Korach KS (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276:36869-36872. doi:10.1074/jbc.R100029200R100029200 [pii]
23. Hall JM, McDonnell DP (1999) The estrogen receptor beta-isoform (erbeta) of the human estrogen receptor modulates eralpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140:5566-5578
24. Hammes SR, Levin ER (2007) Extranuclear steroid receptors: nature and actions. Endocr Rev 28:726-741. doi:er.2007-0022 [pii]10.1210/er.2007-0022
25. Hatzoglou A, Bakogeorgou E, Castanas E (1996a) The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Eur J Pharmacol 296:199-207. doi:0014-2999(95)00703-2[pii]10.1016/0014-2999(95)00703-2
26. Hatzoglou A, Bakogeorgou E, Hatzoglou C, Martin PM, Castanas E (1996b) Antiproliferative and receptor binding properties of alpha- and beta-casomorphins in the T47D human breast cancer cell line. Eur J Pharmacol 310:217-223
27. Howe LR, Brown PH (2011) Targeting the her/egfr/erbb family to prevent breast cancer. Cancer Prev Res (Phila) 4:1149-1157. doi:4/8/1149 [pii]10.1158/1940-6207.CAPR-11-0334
28. Kajdaniuk D, Marek B, Swietochowska E, Ciesielska-Kopacz N, Buntner B (2000) Is positive correlation between cortisol and met-enkephalin concentration in blood of women with breast cancer a reaction to stress before chemotherapy administration? Pathophysiology 7:47-51
29. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494
30. Khan SA, Rogers MA, Obando JA, Tamsen A (1994) Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 54:993-997
31. Koo KL, Tejwani GA, Abou-Issa H (1996) Relative efficacy of the opioid antagonist, naltrexone, on the initiation and promotion phases of rat mammary carcinogenesis. Anticancer Res 16:1893-1898
32. Korach KS, Emmen JM, Walker VR, Hewitt SC, Yates M, Hall JM, Swope DL, Harrell JC, Couse JF (2003) Update on animal models developed for analyses of estrogen receptor biological activity. J Steroid Biochem Mol Biol 86:387-391. doi:S0960076003003480[pii]
33. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O (1998) Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A 95:15677-15682
34. Kugawa F, Arae K, Ueno A, Aoki M (1998) Buprenorphine hydrochloride induces apoptosis in ng108-15 nerve cells. Eur J Pharmacol 347:105-112. doi:S0014-2999(98)00080-6[pii]
35. Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA (2012) Overexpression of the mu-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. doi:10.1097/ALN.0b013e31824babe2
36. Lissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G (2002) A new neuroimmuno-therapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone. Neuro Endocrinol Lett 23:255-258
37. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O (1993) Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A 90:11162-11166
38. Lunzer MM, Yekkirala A, Hebbel RP, Portoghese PS (2007) Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia. Proc Natl Acad Sci U S A 104:6061-6065. doi:0700295104 [pii]10.1073/pnas.0700295104
39. Maneckjee R, Minna JD (1992) Nonconventional opioid binding sites mediate growth inhibitory effects of methadone on human lung cancer cells. Proc Natl Acad Sci U S A 89:1169-1173
40. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM (1995) The nuclear receptor superfamily: the second decade. Cell 83:835-839. doi:0092-8674(95)90199-X[pii]
41. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68:826-833. doi:68/3/826 [pii]10.1158/0008-5472.CAN-07-2707
42. Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, Lariviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA (2011) The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 112:558-567. doi:ANE.0b013e31820568af [pii]10.1213/ANE.0b013e31820568af
43. McLaughlin PJ, Zagon IS (2012) The opioid growth factor-opioid growth factor receptor axis: Homeostatic regulator of cell proliferation and its implications for health and disease. Biochem Pharmacol 84:746-755
44. Moss J, Rosow CE (2008) Development of peripheral opioid antagonists’ new insights into opioid effects. Mayo Clin Proc 83:1116-1130. doi:S0025-6196(11)60617-4[pii]10.4065/83.10.1116
45. Nilsson S, Koehler KF, Gustafsson JA (2011) Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov 10:778-792. doi:nrd3551[pii]10.1038/nrd3551
46. Panagiotou S, Hatzoglou A, Calvo F, Martin PM, Castanas E (1998) Modulation of the estrogen-regulated proteins cathepsin D and pS2 by opioid agonists in hormone-sensitive breast cancer cell lines (MCF7 and T47D): evidence for an interaction between the two systems. J Cell Biochem 71:416-428. doi:10.1002/(SICI)1097-4644(19981201)71:3<416::AID-JCB10>3.0.CO;2-Y[pii]
47. Power I (2011) An update on analgesics. Br J Anaesth 107:19-24. doi:aer126 [pii]10.1093/bja/aer126
48. Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11:643-658
49. Sinchak K, Micevych PE (2001) Progesterone blockade of estrogen activation of mu-opioid receptors regulates reproductive behavior. J Neurosci 21:5723-5729. doi:21/15/5723[pii]
50. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J (2006) Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res 72:3-11. doi:S0026-2862(06)00043-4 [pii]10.1016/j.mvr.2006.04.004
51. Singleton PA, Garcia JG, Moss J (2008) Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther 7:1669-1679
52. Singleton PA, Mambetsariev N, Lennon FE, Mathew B, Siegler JH, Moreno-Vinasco L, Salgia R, Moss J, Garcia JG (2010) Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res 2:5. doi:2040-2384-2-5[pii]10.1186/2040-2384-2-5
53. Stephenson EJ, Gupta K (2006) Existence and modus operandi of opioid receptors in endothelium. In: Aird W (ed) The endothelium: a comprehensive reference. Cambridge University Press, Cambridge, MA, pp 451-460
54. Tegeder I, Grosch S, Schmidtko A, Haussler A, Schmidt H, Niederberger E, SchoLich K, Geisslinger G (2003) G protein-independent g1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res 63:1846-1852
55. Tsunashima K (1982) Anticancer effect of naloxone. Proc Jpn Cancer Assoc 425
56. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N (2010) Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila) 3:696-706. doi: 1940-6207.CAPR-10-0076[pii]10.1158/1940-6207.CAPR-10-0076
57. Wu Q, Chambliss K, Umetani M, Mineo C, Shaul PW (2011) Non-nuclear estrogen receptor signaling in the endothelium. J Biol Chem 286:14737-14743. doi:R110.191791[pii]10.1074/jbc.R110.191791
58. Zagon IS, McLaughlin PJ (1983a) Naltrexone modulates tumor response in mice with neuroblastoma. Science 221:671-673
59. Zagon IS, McLaughlin PJ (1983b) Opioid antagonists inhibit the growth of metastatic murine neuroblastoma. Cancer Lett 21:89-94
60. Zagon IS, McLaughlin PJ (1987) Modulation of murine neuroblastoma in nude mice by opioid antagonists. J Natl Cancer Inst 78:141-147
61. Zagon IS, Donahue RN, McLaughlin PJ (2009) Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am J Physiol Regul Integr Comp Physiol 297:R1154-R1161